Predictive Oncology Inc. (POAI) 10-Year Financial Performance & Capital Metrics

POAI • • Industrial / General

HealthcareMedical InstrumentsBiopharma & Life Science ToolsLaboratory Supplies & Services

AboutPredictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.Show more

Revenue $2M -0.2%
EBITDA -$10M +13.7%
Net Income -$12M +12.7%
EPS (Diluted) -2.24 +35.6%
Gross Margin 49.12% -21.5%
EBITDA Margin -630.85% +13.5%
Operating Margin -673.69% +9.5%
Net Margin -751.39% +12.5%
ROE -302.42% -224.8%
ROIC -473.83% +44.1%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 35.8% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.49%

5Y2.84%

3Y4.56%

TTM-47.2%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-503.68%

EPS CAGR

10Y-

5Y-

3Y-

TTM-3436.58%

ROCE

10Y Avg-247.91%

5Y Avg-153.72%

3Y Avg-114.39%

Latest-184.71%

Peer Comparison

Laboratory Supplies & Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AVTRAvantor, Inc.	8.2B	12.02	11.56	-2.64%	10.31%	10.94%	8.44%	0.71
POAIPredictive Oncology Inc.	24.03M	7.08	-3.16	-0.24%	-115.81%	-302.42%
AZTAAzenta, Inc.	1.84B	39.91	-30.70	-9.52%	-10.01%	-3.45%	2.09%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	654.35K	456.5K	654.84K	1.41M	1.41M	1.25M	1.42M	1.51M	1.63M	1.62M
Revenue Growth %	-0.31%	-0.3%	0.43%	1.16%	-0%	-0.11%	0.13%	0.06%	0.08%	-0%
Cost of Goods Sold+	303.98K	181.62K	148.04K	415.76K	531.81K	447.19K	487.02K	505.11K	609.21K	826.14K
COGS % of Revenue	0.46%	0.4%	0.23%	0.29%	0.38%	0.36%	0.34%	0.34%	0.37%	0.51%
Gross Profit+	350.37K	274.88K	506.79K	995.89K	879.75K	805.08K	933.66K	1M	1.02M	797.68K
Gross Margin %	0.54%	0.6%	0.77%	0.71%	0.62%	0.64%	0.66%	0.66%	0.63%	0.49%
Gross Profit Growth %	-0.38%	-0.22%	0.84%	0.97%	-0.12%	-0.08%	0.16%	0.07%	0.02%	-0.22%
Operating Expenses+	4.75M	6.8M	8.25M	8.86M	23.52M	26.17M	21.36M	27.03M	13.14M	11.74M
OpEx % of Revenue	7.26%	14.9%	12.6%	6.27%	16.67%	20.89%	15.04%	17.96%	8.07%	7.23%
Selling, General & Admin	4.75M	5.64M	8.25M	7M	11.69M	10.94M	11.71M	12.47M	9.06M	8.89M
SG&A % of Revenue	7.26%	12.36%	12.6%	4.96%	8.28%	8.73%	8.24%	8.28%	5.56%	5.47%
Research & Development	261K	406K	289K	1.86M	2.96M	372.71K	315.85K	320.32K	122.31K	25.99K
R&D % of Revenue	0.4%	0.89%	0.44%	1.32%	2.1%	0.3%	0.22%	0.21%	0.08%	0.02%
Other Operating Expenses	0	1.16M	0	68.48K	8.87M	14.86M	9.34M	14.24M	3.96M	2.83M
Operating Income+	-4.4M	-6.53M	-7.75M	-7.86M	-22.64M	-25.36M	-20.43M	-26.03M	-12.12M	-10.94M
Operating Margin %	-6.72%	-14.3%	-11.83%	-5.57%	-16.04%	-20.25%	-14.38%	-17.29%	-7.44%	-6.74%
Operating Income Growth %	0.32%	-0.48%	-0.19%	-0.01%	-1.88%	-0.12%	0.19%	-0.27%	0.53%	0.1%
EBITDA+	-4.32M	-6.44M	-7.68M	-7.71M	-21.94M	-24.34M	-19.09M	-24.72M	-11.87M	-10.24M
EBITDA Margin %	-6.6%	-14.12%	-11.72%	-5.46%	-15.54%	-19.43%	-13.44%	-16.42%	-7.29%	-6.31%
EBITDA Growth %	0.33%	-0.49%	-0.19%	-0.01%	-1.84%	-0.11%	0.22%	-0.3%	0.52%	0.14%
D&A (Non-Cash Add-back)	78.57K	82.36K	71.56K	147.63K	704.88K	1.02M	1.34M	1.31M	244.79K	695.66K
EBIT	-4.4M	-6.53M	-6.05M	-7.86M	-13.77M	-12.48M	-13.47M	-15.27M	-12.12M	-10.94M
Net Interest Income+	-390.89K	-3	0	0	0	0	0	-10.65M	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	390.89K	3	0	0	0	0	0	10.65M	0	0
Other Income/Expense	-390.89K	-3	50.51K	-2.23M	3.25M	-524.36K	109.8K	296.02K	100.17K	79.27K
Pretax Income+	-4.79M	-6.53M	-7.75M	-10.09M	-19.39M	-25.88M	-20.32M	-25.74M	-12.02M	-10.86M
Pretax Margin %	-7.32%	-14.3%	-11.83%	-7.15%	-13.74%	-20.67%	-14.3%	-17.1%	-7.38%	-6.69%
Income Tax+	0	0	50.5K	0	0	0	-661.66K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.97%	1%	1.16%	1.12%
Net Income+	-4.79M	-6.53M	-7.75M	-10.09M	-19.39M	-25.88M	-19.66M	-25.74M	-13.98M	-12.2M
Net Margin %	-7.32%	-14.3%	-11.83%	-7.15%	-13.74%	-20.67%	-13.84%	-17.1%	-8.59%	-7.51%
Net Income Growth %	0.3%	-0.36%	-0.19%	-0.3%	-0.92%	-0.33%	0.24%	-0.31%	0.46%	0.13%
Net Income (Continuing)	-4.79M	-6.53M	-6M	-10.09M	-19.39M	-25.88M	-19.66M	-25.74M	-12.02M	-10.86M
Discontinued Operations	0	0	0	0	0	0	0	0	-1.97M	-1.8M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-306.79	-462.28	-188.69	-157.40	-137.20	-44.25	-7.20	-6.98	-3.48	-2.24
EPS Growth %	0.58%	-0.51%	0.59%	0.17%	0.13%	0.68%	0.84%	0.03%	0.5%	0.36%
EPS (Basic)	-306.79	-462.28	-188.69	-157.40	-137.14	-44.25	-7.16	-6.98	-3.48	-2.24
Diluted Shares Outstanding	15.62K	14.12K	31.82K	64.08K	143.5K	597.51K	2.74M	3.69M	4.01M	5.45M
Basic Shares Outstanding	15.62K	14.12K	31.82K	64.08K	141.33K	584.99K	2.73M	3.69M	4.01M	5.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.4M	2.61M	2.37M	1.45M	798.26K	1.51M	29.46M	23.36M	10.08M	2.23M
Cash & Short-Term Investments	4.86M	2.05M	766.19K	162.15K	150.83K	678.33K	28.2M	22.07M	8.73M	734.67K
Cash Only	4.86M	1.76M	766.19K	162.15K	150.83K	678.33K	28.2M	22.07M	8.73M	734.67K
Short-Term Investments	0	284.33K	0	0	0	0	0	0	0	0
Accounts Receivable	38.28K	38.92K	805.01K	729.88K	297.06K	256.88K	354.2K	331.2K	277.64K	745.57K
Days Sales Outstanding	21.35	31.12	448.71	188.72	76.81	74.87	91	80.3	62.26	167.59
Inventory	231.74K	272.21K	265.05K	241.07K	190.16K	289.54K	387.68K	430.49K	480.8K	385.73K
Days Inventory Outstanding	278.26	547.05	653.46	211.63	130.51	236.32	290.55	311.08	288.07	170.42
Other Current Assets	271.58K	0	0	0	0	0	0	526.8K	69.63K	359.95K
Total Non-Current Assets+	234.59K	199.36K	1.25M	2.26M	21.58M	11.55M	14.31M	2.37M	4.34M	2.75M
Property, Plant & Equipment	139.6K	101.5K	87.72K	180.45K	2.24M	5.22M	3.33M	2.05M	3.96M	2.43M
Fixed Asset Turnover	4.69x	4.50x	7.47x	7.82x	0.63x	0.24x	0.43x	0.74x	0.41x	0.67x
Goodwill	0	0	0	0	15.69M	2.81M	6.86M	0	0	0
Intangible Assets	94.99K	97.87K	95.36K	964.5K	3.65M	3.4M	3.96M	253.87K	252.46K	210.11K
Long-Term Investments	0	0	1.07M	1.11M	0	0	0	0	0	0
Other Non-Current Assets	0	0	1.07M	1.11M	0	116.26K	167.06K	75.62K	124.1K	102.51K
Total Assets+	5.63M	2.81M	3.62M	3.71M	22.38M	13.06M	43.77M	25.73M	14.42M	4.97M
Asset Turnover	0.12x	0.16x	0.18x	0.38x	0.06x	0.10x	0.03x	0.06x	0.11x	0.33x
Asset Growth %	5.25%	-0.5%	0.29%	0.02%	5.03%	-0.42%	2.35%	-0.41%	-0.44%	-0.66%
Total Current Liabilities+	1.52M	1.57M	932.34K	3.66M	10.87M	9.34M	3.24M	3.88M	3.95M	3.59M
Accounts Payable	650.41K	220.11K	140.46K	445.69K	3.16M	1.37M	1.02M	943.45K	1.33M	1.14M
Days Payables Outstanding	780.97	442.36	346.3	391.27	2.17K	1.12K	765.77	681.76	799.28	504.96
Short-Term Debt	0	0	0	1.63M	5.26M	4.43M	0	0	150.41K	0
Deferred Revenue (Current)	5K	8K	6.66K	23.07K	40.38K	53.03K	186.95K	602.07K	302.5K	304.99K
Other Current Liabilities	0	0	0	272.75K	-408.49K	294.38K	129.48K	13.83K	176.22K	164.77K
Current Ratio	3.55x	1.66x	2.54x	0.40x	0.07x	0.16x	9.09x	6.02x	2.55x	0.62x
Quick Ratio	3.40x	1.48x	2.26x	0.33x	0.06x	0.13x	8.97x	5.91x	2.43x	0.51x
Cash Conversion Cycle	-481.36	135.82	755.86	9.08	-1.96K	-808.7	-384.22	-290.38	-448.96	-166.95
Total Non-Current Liabilities+	0	309.65K	0	0	270.26K	1.08M	265.08K	86.08K	2.19M	1.58M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	270.26K	845.13K	239.66K	86.08K	2.13M	1.56M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	309.65K	0	0	0	235.71K	25.41K	0	63.46K	23.49K
Total Liabilities	1.52M	1.88M	932.34K	3.66M	11.14M	10.42M	3.51M	3.97M	6.15M	5.18M
Total Debt+	0	0	0	1.63M	5.99M	5.87M	879.33K	180.32K	2.73M	2.13M
Net Debt	-4.86M	-1.76M	-766.19K	1.47M	5.83M	5.2M	-27.32M	-21.89M	-6M	1.4M
Debt / Equity	-	-	-	30.58x	0.53x	2.22x	0.02x	0.01x	0.33x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-11.26x	-999999.00x	-	-	-	-	-	-2.44x	-	-
Total Equity+	4.11M	923.68K	2.69M	53.47K	11.23M	2.64M	40.27M	21.77M	8.27M	-202.61K
Equity Growth %	1.75%	-0.78%	1.91%	-0.98%	209.04%	-0.76%	14.24%	-0.46%	-0.62%	-1.02%
Book Value per Share	263.38	65.44	84.61	0.83	78.26	4.42	14.68	5.91	2.06	-0.04
Total Shareholders' Equity	4.11M	923.68K	2.69M	53.47K	11.23M	2.64M	40.27M	21.77M	8.27M	-202.61K
Common Stock	52.06K	45.64K	69.43K	140.92K	40.57K	198.05K	656.15K	39.38K	40.63K	66.67K
Retained Earnings	-40.49M	-47.02M	-54.77M	-63.11M	-82.5M	-108.38M	-128.04M	-153.78M	-167.76M	-180.43M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-144.08K	1.5K	-273.77K	-358.76K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.49M	-4.38M	-4.46M	-5.29M	-8.73M	-12.26M	-12.21M	-12.37M	-13.19M	-11.96M
Operating CF Margin %	-11.44%	-9.6%	-6.81%	-3.75%	-6.19%	-9.79%	-8.59%	-8.22%	-8.1%	-7.36%
Operating CF Growth %	-1.22%	0.41%	-0.02%	-0.19%	-0.65%	-0.4%	0%	-0.01%	-0.07%	0.09%
Net Income	-4.79M	-6.53M	-7.75M	-10.09M	-19.39M	-25.88M	-19.66M	-25.74M	-12.02M	-10.86M
Depreciation & Amortization	78.57K	82.36K	71.56K	147.63K	704.88K	1.02M	1.34M	1.31M	724.81K	695.66K
Stock-Based Compensation	871.88K	886.6K	4.04M	1.46M	0	1.17M	921.13K	522.44K	0	0
Deferred Taxes	246.2K	0	-1.84K	0	0	-1.17M	-661.66K	-522.44K	0	0
Other Non-Cash Items	-6.67K	1.62M	359.13K	3.77M	8.08M	13.81M	7.04M	11.19M	-1.12M	-876.57K
Working Capital Changes	-3.89M	446K	-1.18M	884.3K	1.87M	-1.21M	-1.19M	866.69K	-780.36K	-914.56K
Change in Receivables	19.27K	-636	-98.58K	-95.1K	143.32K	69.91K	-20.77K	23K	19K	-467.93K
Change in Inventory	135.63K	-40.47K	7.16K	23.98K	91.11K	-94.72K	-98.15K	-42.81K	-65.45K	95.08K
Change in Payables	-1.54M	-430.3K	-79.65K	305.23K	365.77K	-1.66M	-350.3K	-78.32K	399.21K	-191.15K
Cash from Investing+	-60.56K	-422.86K	-1.65M	-1.11M	-599.09K	-167.46K	-10.61M	-475.7K	-302.37K	22.49K
Capital Expenditures	-60.56K	-44.75K	-55.27K	-232K	-5.89K	-360.78K	-962.32K	-475.7K	-47.55K	-9.51K
CapEx % of Revenue	0.09%	0.1%	0.08%	0.16%	0%	0.29%	0.68%	0.32%	0.03%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-28.09K	-88.01K	-1.88M	-1.12M	-841.3K	0	-55K	0	-254.82K	32K
Cash from Financing+	12.39M	1.71M	5.11M	5.79M	9.32M	12.95M	50.34M	6.72M	148.9K	3.94M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	650.06K	-196.32K	1.71M	4.39M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.55M	-4.43M	-4.52M	-5.52M	-8.76M	-12.62M	-13.17M	-12.85M	-13.21M	-11.97M
FCF Margin %	-11.53%	-9.7%	-6.89%	-3.91%	-6.21%	-10.08%	-9.27%	-8.53%	-8.12%	-7.37%
FCF Growth %	-1.16%	0.41%	-0.02%	-0.22%	-0.59%	-0.44%	-0.04%	0.02%	-0.03%	0.09%
FCF per Share	-483.37	-313.58	-141.91	-86.14	-61.04	-21.12	-4.80	-3.49	-3.29	-2.19
FCF Conversion (FCF/Net Income)	1.56x	0.67x	0.58x	0.52x	0.45x	0.47x	0.62x	0.48x	0.94x	0.98x
Interest Paid	0	0	0	0	146.06K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-116.48%	-259.15%	-428.51%	-734.79%	-343.66%	-373.14%	-91.62%	-82.98%	-93.11%	-302.42%
Return on Invested Capital (ROIC)	-	-	-1070.64%	-341.61%	-182.7%	-152.74%	-147.45%	-304.68%	-847.75%	-473.83%
Gross Margin	53.54%	60.21%	77.39%	70.55%	62.32%	64.29%	65.72%	66.45%	62.57%	49.12%
Net Margin	-732.1%	-1429.59%	-1182.98%	-714.51%	-1373.71%	-2066.99%	-1383.65%	-1709.62%	-859.13%	-751.39%
Debt / Equity	-	-	-	30.58x	0.53x	2.22x	0.02x	0.01x	0.33x	-
Interest Coverage	-11.26x	-999999.00x	-	-	-	-	-	-2.44x	-	-
FCF Conversion	1.56x	0.67x	0.58x	0.52x	0.45x	0.47x	0.62x	0.48x	0.94x	0.98x
Revenue Growth	-31.23%	-30.24%	43.45%	115.57%	-0.01%	-11.28%	13.45%	5.97%	8.12%	-0.24%

Revenue by Segment

	2017	2019	2020	2021	2022	2023	2024
Pittsburgh	-	-	-	-	-	492.6K	84.81K
Pittsburgh Growth	-	-	-	-	-	-	-82.78%
Skyline	-	-	1.19M	1.17M	1.06M	-	-
Skyline Growth	-	-	-	-1.30%	-9.09%	-	-
zPREDICTA	-	-	-	90	352.38K	-	-
zPREDICTA Growth	-	-	-	-	391432.22%	-	-
Soluble	-	-	2.87K	233.29K	82.3K	-	-
Soluble Growth	-	-	-	8028.68%	-64.72%	-	-
Helomics	-	48.45K	64.19K	13.37K	6.4K	-	-
Helomics Growth	-	-	32.49%	-79.18%	-52.14%	-	-
Domestic	-	1.28M	-	-	-	-	-
Domestic Growth	-	-	-	-	-	-	-
International	-	88.07K	-	-	-	-	-
International Growth	-	-	-	-	-	-	-

Revenue by Geography

	2017	2019	2020	2021	2022	2023	2024
Domestic	-	1.28M	-	-	-	-	-
Domestic Growth	-	-	-	-	-	-	-
Non-US	26.66K	-	-	-	-	-	-
Non-US Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Predictive Oncology Inc. (POAI) reported $0.7M in revenue for fiscal year 2024. This represents a 654% increase from $0.1M in 2011.

Predictive Oncology Inc. (POAI) saw revenue decline by 0.2% over the past year.

Predictive Oncology Inc. (POAI) reported a net loss of $84.3M for fiscal year 2024.

Dividend & Returns

Predictive Oncology Inc. (POAI) has a return on equity (ROE) of -302.4%. Negative ROE indicates the company is unprofitable.

Predictive Oncology Inc. (POAI) had negative free cash flow of $8.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Predictive Oncology Inc. (POAI) 10-Year Financial Performance & Capital Metrics

POAI • • Industrial / General

HealthcareMedical InstrumentsBiopharma & Life Science ToolsLaboratory Supplies & Services

Revenue $2M -0.2%
EBITDA -$10M +13.7%
Net Income -$12M +12.7%
EPS (Diluted) -2.24 +35.6%
Gross Margin 49.12% -21.5%
EBITDA Margin -630.85% +13.5%
Operating Margin -673.69% +9.5%
Net Margin -751.39% +12.5%
ROE -302.42% -224.8%
ROIC -473.83% +44.1%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 35.8% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.49%

5Y2.84%

3Y4.56%

TTM-47.2%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-503.68%

EPS CAGR

10Y-

5Y-

3Y-

TTM-3436.58%

ROCE

10Y Avg-247.91%

5Y Avg-153.72%

3Y Avg-114.39%

Latest-184.71%

Peer Comparison

Laboratory Supplies & Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AVTRAvantor, Inc.	8.2B	12.02	11.56	-2.64%	10.31%	10.94%	8.44%	0.71
POAIPredictive Oncology Inc.	24.03M	7.08	-3.16	-0.24%	-115.81%	-302.42%
AZTAAzenta, Inc.	1.84B	39.91	-30.70	-9.52%	-10.01%	-3.45%	2.09%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	654.35K	456.5K	654.84K	1.41M	1.41M	1.25M	1.42M	1.51M	1.63M	1.62M
Revenue Growth %	-0.31%	-0.3%	0.43%	1.16%	-0%	-0.11%	0.13%	0.06%	0.08%	-0%
Cost of Goods Sold+	303.98K	181.62K	148.04K	415.76K	531.81K	447.19K	487.02K	505.11K	609.21K	826.14K
COGS % of Revenue	0.46%	0.4%	0.23%	0.29%	0.38%	0.36%	0.34%	0.34%	0.37%	0.51%
Gross Profit+	350.37K	274.88K	506.79K	995.89K	879.75K	805.08K	933.66K	1M	1.02M	797.68K
Gross Margin %	0.54%	0.6%	0.77%	0.71%	0.62%	0.64%	0.66%	0.66%	0.63%	0.49%
Gross Profit Growth %	-0.38%	-0.22%	0.84%	0.97%	-0.12%	-0.08%	0.16%	0.07%	0.02%	-0.22%
Operating Expenses+	4.75M	6.8M	8.25M	8.86M	23.52M	26.17M	21.36M	27.03M	13.14M	11.74M
OpEx % of Revenue	7.26%	14.9%	12.6%	6.27%	16.67%	20.89%	15.04%	17.96%	8.07%	7.23%
Selling, General & Admin	4.75M	5.64M	8.25M	7M	11.69M	10.94M	11.71M	12.47M	9.06M	8.89M
SG&A % of Revenue	7.26%	12.36%	12.6%	4.96%	8.28%	8.73%	8.24%	8.28%	5.56%	5.47%
Research & Development	261K	406K	289K	1.86M	2.96M	372.71K	315.85K	320.32K	122.31K	25.99K
R&D % of Revenue	0.4%	0.89%	0.44%	1.32%	2.1%	0.3%	0.22%	0.21%	0.08%	0.02%
Other Operating Expenses	0	1.16M	0	68.48K	8.87M	14.86M	9.34M	14.24M	3.96M	2.83M
Operating Income+	-4.4M	-6.53M	-7.75M	-7.86M	-22.64M	-25.36M	-20.43M	-26.03M	-12.12M	-10.94M
Operating Margin %	-6.72%	-14.3%	-11.83%	-5.57%	-16.04%	-20.25%	-14.38%	-17.29%	-7.44%	-6.74%
Operating Income Growth %	0.32%	-0.48%	-0.19%	-0.01%	-1.88%	-0.12%	0.19%	-0.27%	0.53%	0.1%
EBITDA+	-4.32M	-6.44M	-7.68M	-7.71M	-21.94M	-24.34M	-19.09M	-24.72M	-11.87M	-10.24M
EBITDA Margin %	-6.6%	-14.12%	-11.72%	-5.46%	-15.54%	-19.43%	-13.44%	-16.42%	-7.29%	-6.31%
EBITDA Growth %	0.33%	-0.49%	-0.19%	-0.01%	-1.84%	-0.11%	0.22%	-0.3%	0.52%	0.14%
D&A (Non-Cash Add-back)	78.57K	82.36K	71.56K	147.63K	704.88K	1.02M	1.34M	1.31M	244.79K	695.66K
EBIT	-4.4M	-6.53M	-6.05M	-7.86M	-13.77M	-12.48M	-13.47M	-15.27M	-12.12M	-10.94M
Net Interest Income+	-390.89K	-3	0	0	0	0	0	-10.65M	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	390.89K	3	0	0	0	0	0	10.65M	0	0
Other Income/Expense	-390.89K	-3	50.51K	-2.23M	3.25M	-524.36K	109.8K	296.02K	100.17K	79.27K
Pretax Income+	-4.79M	-6.53M	-7.75M	-10.09M	-19.39M	-25.88M	-20.32M	-25.74M	-12.02M	-10.86M
Pretax Margin %	-7.32%	-14.3%	-11.83%	-7.15%	-13.74%	-20.67%	-14.3%	-17.1%	-7.38%	-6.69%
Income Tax+	0	0	50.5K	0	0	0	-661.66K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.97%	1%	1.16%	1.12%
Net Income+	-4.79M	-6.53M	-7.75M	-10.09M	-19.39M	-25.88M	-19.66M	-25.74M	-13.98M	-12.2M
Net Margin %	-7.32%	-14.3%	-11.83%	-7.15%	-13.74%	-20.67%	-13.84%	-17.1%	-8.59%	-7.51%
Net Income Growth %	0.3%	-0.36%	-0.19%	-0.3%	-0.92%	-0.33%	0.24%	-0.31%	0.46%	0.13%
Net Income (Continuing)	-4.79M	-6.53M	-6M	-10.09M	-19.39M	-25.88M	-19.66M	-25.74M	-12.02M	-10.86M
Discontinued Operations	0	0	0	0	0	0	0	0	-1.97M	-1.8M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-306.79	-462.28	-188.69	-157.40	-137.20	-44.25	-7.20	-6.98	-3.48	-2.24
EPS Growth %	0.58%	-0.51%	0.59%	0.17%	0.13%	0.68%	0.84%	0.03%	0.5%	0.36%
EPS (Basic)	-306.79	-462.28	-188.69	-157.40	-137.14	-44.25	-7.16	-6.98	-3.48	-2.24
Diluted Shares Outstanding	15.62K	14.12K	31.82K	64.08K	143.5K	597.51K	2.74M	3.69M	4.01M	5.45M
Basic Shares Outstanding	15.62K	14.12K	31.82K	64.08K	141.33K	584.99K	2.73M	3.69M	4.01M	5.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.4M	2.61M	2.37M	1.45M	798.26K	1.51M	29.46M	23.36M	10.08M	2.23M
Cash & Short-Term Investments	4.86M	2.05M	766.19K	162.15K	150.83K	678.33K	28.2M	22.07M	8.73M	734.67K
Cash Only	4.86M	1.76M	766.19K	162.15K	150.83K	678.33K	28.2M	22.07M	8.73M	734.67K
Short-Term Investments	0	284.33K	0	0	0	0	0	0	0	0
Accounts Receivable	38.28K	38.92K	805.01K	729.88K	297.06K	256.88K	354.2K	331.2K	277.64K	745.57K
Days Sales Outstanding	21.35	31.12	448.71	188.72	76.81	74.87	91	80.3	62.26	167.59
Inventory	231.74K	272.21K	265.05K	241.07K	190.16K	289.54K	387.68K	430.49K	480.8K	385.73K
Days Inventory Outstanding	278.26	547.05	653.46	211.63	130.51	236.32	290.55	311.08	288.07	170.42
Other Current Assets	271.58K	0	0	0	0	0	0	526.8K	69.63K	359.95K
Total Non-Current Assets+	234.59K	199.36K	1.25M	2.26M	21.58M	11.55M	14.31M	2.37M	4.34M	2.75M
Property, Plant & Equipment	139.6K	101.5K	87.72K	180.45K	2.24M	5.22M	3.33M	2.05M	3.96M	2.43M
Fixed Asset Turnover	4.69x	4.50x	7.47x	7.82x	0.63x	0.24x	0.43x	0.74x	0.41x	0.67x
Goodwill	0	0	0	0	15.69M	2.81M	6.86M	0	0	0
Intangible Assets	94.99K	97.87K	95.36K	964.5K	3.65M	3.4M	3.96M	253.87K	252.46K	210.11K
Long-Term Investments	0	0	1.07M	1.11M	0	0	0	0	0	0
Other Non-Current Assets	0	0	1.07M	1.11M	0	116.26K	167.06K	75.62K	124.1K	102.51K
Total Assets+	5.63M	2.81M	3.62M	3.71M	22.38M	13.06M	43.77M	25.73M	14.42M	4.97M
Asset Turnover	0.12x	0.16x	0.18x	0.38x	0.06x	0.10x	0.03x	0.06x	0.11x	0.33x
Asset Growth %	5.25%	-0.5%	0.29%	0.02%	5.03%	-0.42%	2.35%	-0.41%	-0.44%	-0.66%
Total Current Liabilities+	1.52M	1.57M	932.34K	3.66M	10.87M	9.34M	3.24M	3.88M	3.95M	3.59M
Accounts Payable	650.41K	220.11K	140.46K	445.69K	3.16M	1.37M	1.02M	943.45K	1.33M	1.14M
Days Payables Outstanding	780.97	442.36	346.3	391.27	2.17K	1.12K	765.77	681.76	799.28	504.96
Short-Term Debt	0	0	0	1.63M	5.26M	4.43M	0	0	150.41K	0
Deferred Revenue (Current)	5K	8K	6.66K	23.07K	40.38K	53.03K	186.95K	602.07K	302.5K	304.99K
Other Current Liabilities	0	0	0	272.75K	-408.49K	294.38K	129.48K	13.83K	176.22K	164.77K
Current Ratio	3.55x	1.66x	2.54x	0.40x	0.07x	0.16x	9.09x	6.02x	2.55x	0.62x
Quick Ratio	3.40x	1.48x	2.26x	0.33x	0.06x	0.13x	8.97x	5.91x	2.43x	0.51x
Cash Conversion Cycle	-481.36	135.82	755.86	9.08	-1.96K	-808.7	-384.22	-290.38	-448.96	-166.95
Total Non-Current Liabilities+	0	309.65K	0	0	270.26K	1.08M	265.08K	86.08K	2.19M	1.58M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	270.26K	845.13K	239.66K	86.08K	2.13M	1.56M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	309.65K	0	0	0	235.71K	25.41K	0	63.46K	23.49K
Total Liabilities	1.52M	1.88M	932.34K	3.66M	11.14M	10.42M	3.51M	3.97M	6.15M	5.18M
Total Debt+	0	0	0	1.63M	5.99M	5.87M	879.33K	180.32K	2.73M	2.13M
Net Debt	-4.86M	-1.76M	-766.19K	1.47M	5.83M	5.2M	-27.32M	-21.89M	-6M	1.4M
Debt / Equity	-	-	-	30.58x	0.53x	2.22x	0.02x	0.01x	0.33x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-11.26x	-999999.00x	-	-	-	-	-	-2.44x	-	-
Total Equity+	4.11M	923.68K	2.69M	53.47K	11.23M	2.64M	40.27M	21.77M	8.27M	-202.61K
Equity Growth %	1.75%	-0.78%	1.91%	-0.98%	209.04%	-0.76%	14.24%	-0.46%	-0.62%	-1.02%
Book Value per Share	263.38	65.44	84.61	0.83	78.26	4.42	14.68	5.91	2.06	-0.04
Total Shareholders' Equity	4.11M	923.68K	2.69M	53.47K	11.23M	2.64M	40.27M	21.77M	8.27M	-202.61K
Common Stock	52.06K	45.64K	69.43K	140.92K	40.57K	198.05K	656.15K	39.38K	40.63K	66.67K
Retained Earnings	-40.49M	-47.02M	-54.77M	-63.11M	-82.5M	-108.38M	-128.04M	-153.78M	-167.76M	-180.43M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-144.08K	1.5K	-273.77K	-358.76K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.49M	-4.38M	-4.46M	-5.29M	-8.73M	-12.26M	-12.21M	-12.37M	-13.19M	-11.96M
Operating CF Margin %	-11.44%	-9.6%	-6.81%	-3.75%	-6.19%	-9.79%	-8.59%	-8.22%	-8.1%	-7.36%
Operating CF Growth %	-1.22%	0.41%	-0.02%	-0.19%	-0.65%	-0.4%	0%	-0.01%	-0.07%	0.09%
Net Income	-4.79M	-6.53M	-7.75M	-10.09M	-19.39M	-25.88M	-19.66M	-25.74M	-12.02M	-10.86M
Depreciation & Amortization	78.57K	82.36K	71.56K	147.63K	704.88K	1.02M	1.34M	1.31M	724.81K	695.66K
Stock-Based Compensation	871.88K	886.6K	4.04M	1.46M	0	1.17M	921.13K	522.44K	0	0
Deferred Taxes	246.2K	0	-1.84K	0	0	-1.17M	-661.66K	-522.44K	0	0
Other Non-Cash Items	-6.67K	1.62M	359.13K	3.77M	8.08M	13.81M	7.04M	11.19M	-1.12M	-876.57K
Working Capital Changes	-3.89M	446K	-1.18M	884.3K	1.87M	-1.21M	-1.19M	866.69K	-780.36K	-914.56K
Change in Receivables	19.27K	-636	-98.58K	-95.1K	143.32K	69.91K	-20.77K	23K	19K	-467.93K
Change in Inventory	135.63K	-40.47K	7.16K	23.98K	91.11K	-94.72K	-98.15K	-42.81K	-65.45K	95.08K
Change in Payables	-1.54M	-430.3K	-79.65K	305.23K	365.77K	-1.66M	-350.3K	-78.32K	399.21K	-191.15K
Cash from Investing+	-60.56K	-422.86K	-1.65M	-1.11M	-599.09K	-167.46K	-10.61M	-475.7K	-302.37K	22.49K
Capital Expenditures	-60.56K	-44.75K	-55.27K	-232K	-5.89K	-360.78K	-962.32K	-475.7K	-47.55K	-9.51K
CapEx % of Revenue	0.09%	0.1%	0.08%	0.16%	0%	0.29%	0.68%	0.32%	0.03%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-28.09K	-88.01K	-1.88M	-1.12M	-841.3K	0	-55K	0	-254.82K	32K
Cash from Financing+	12.39M	1.71M	5.11M	5.79M	9.32M	12.95M	50.34M	6.72M	148.9K	3.94M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	650.06K	-196.32K	1.71M	4.39M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.55M	-4.43M	-4.52M	-5.52M	-8.76M	-12.62M	-13.17M	-12.85M	-13.21M	-11.97M
FCF Margin %	-11.53%	-9.7%	-6.89%	-3.91%	-6.21%	-10.08%	-9.27%	-8.53%	-8.12%	-7.37%
FCF Growth %	-1.16%	0.41%	-0.02%	-0.22%	-0.59%	-0.44%	-0.04%	0.02%	-0.03%	0.09%
FCF per Share	-483.37	-313.58	-141.91	-86.14	-61.04	-21.12	-4.80	-3.49	-3.29	-2.19
FCF Conversion (FCF/Net Income)	1.56x	0.67x	0.58x	0.52x	0.45x	0.47x	0.62x	0.48x	0.94x	0.98x
Interest Paid	0	0	0	0	146.06K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-116.48%	-259.15%	-428.51%	-734.79%	-343.66%	-373.14%	-91.62%	-82.98%	-93.11%	-302.42%
Return on Invested Capital (ROIC)	-	-	-1070.64%	-341.61%	-182.7%	-152.74%	-147.45%	-304.68%	-847.75%	-473.83%
Gross Margin	53.54%	60.21%	77.39%	70.55%	62.32%	64.29%	65.72%	66.45%	62.57%	49.12%
Net Margin	-732.1%	-1429.59%	-1182.98%	-714.51%	-1373.71%	-2066.99%	-1383.65%	-1709.62%	-859.13%	-751.39%
Debt / Equity	-	-	-	30.58x	0.53x	2.22x	0.02x	0.01x	0.33x	-
Interest Coverage	-11.26x	-999999.00x	-	-	-	-	-	-2.44x	-	-
FCF Conversion	1.56x	0.67x	0.58x	0.52x	0.45x	0.47x	0.62x	0.48x	0.94x	0.98x
Revenue Growth	-31.23%	-30.24%	43.45%	115.57%	-0.01%	-11.28%	13.45%	5.97%	8.12%	-0.24%

Revenue by Segment

	2017	2019	2020	2021	2022	2023	2024
Pittsburgh	-	-	-	-	-	492.6K	84.81K
Pittsburgh Growth	-	-	-	-	-	-	-82.78%
Skyline	-	-	1.19M	1.17M	1.06M	-	-
Skyline Growth	-	-	-	-1.30%	-9.09%	-	-
zPREDICTA	-	-	-	90	352.38K	-	-
zPREDICTA Growth	-	-	-	-	391432.22%	-	-
Soluble	-	-	2.87K	233.29K	82.3K	-	-
Soluble Growth	-	-	-	8028.68%	-64.72%	-	-
Helomics	-	48.45K	64.19K	13.37K	6.4K	-	-
Helomics Growth	-	-	32.49%	-79.18%	-52.14%	-	-
Domestic	-	1.28M	-	-	-	-	-
Domestic Growth	-	-	-	-	-	-	-
International	-	88.07K	-	-	-	-	-
International Growth	-	-	-	-	-	-	-

Revenue by Geography

	2017	2019	2020	2021	2022	2023	2024
Domestic	-	1.28M	-	-	-	-	-
Domestic Growth	-	-	-	-	-	-	-
Non-US	26.66K	-	-	-	-	-	-
Non-US Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Predictive Oncology Inc. (POAI) reported $0.7M in revenue for fiscal year 2024. This represents a 654% increase from $0.1M in 2011.

Predictive Oncology Inc. (POAI) saw revenue decline by 0.2% over the past year.

Predictive Oncology Inc. (POAI) reported a net loss of $84.3M for fiscal year 2024.

Dividend & Returns

Predictive Oncology Inc. (POAI) has a return on equity (ROE) of -302.4%. Negative ROE indicates the company is unprofitable.

Predictive Oncology Inc. (POAI) had negative free cash flow of $8.8M in fiscal year 2024, likely due to heavy capital investments.